Steven Edens, MD
Ophthalmology · West Palm Beach, FLNPI 1215468863
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,447 of the $6,795 with a category attached, or 80.2%. 24 manufacturers reported payments, led by Alcon at 36.1% of the total.
Across 136 payments — averaging $49.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$877
- Bausch & Lomb Americas Inc.$667
- Tarsus Pharmaceuticals, Inc.$572
- Harrow Eye, LLC$321
- Sun Pharmaceutical Industries Inc.$283
- plus $2K from 18 others
What the payments were for
- Travel & lodging$1,27219%
- Food & beverage$5,44780%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 27 | $2,451 |
| AbbVie(2 entities) | 30 | $877 |
| Bausch & Lomb Americas Inc. | 10 | $667 |
| Tarsus Pharmaceuticals, Inc. | 13 | $572 |
| Harrow Eye, LLC | 6 | $321 |
| Sun Pharmaceutical Industries Inc. | 4 | $283 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $209 |
| Dompe US, Inc. | 4 | $196 |
| Sight Sciences, Inc. | 3 | $192 |
| Regeneron Healthcare Solutions, Inc. | 2 | $154 |
| Novartis | 8 | $150 |
| Genentech USA, Inc. | 4 | $107 |
| NEW World Medical,inc. | 1 | $105 |
| Glaukos Corporation | 4 | $82 |
| Oyster Point Pharma, Inc. | 4 | $79 |
| Apellis Pharmaceuticals, Inc. | 3 | $78 |
| Eyevance Pharmaceuticals LLC | 1 | $76 |
| Astellas Pharma US Inc | 2 | $52 |
| Oculus Surgical Inc. | 1 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Coopervision Inc. | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$1,566
- MIEBO$451
- XDEMVY$284
- Clareon$274
- CEQUA$227
- XIIDRA$219
- Hydrus Microstent$150
- OMNI(R) SURGICAL SYSTEM (US)$146
- SION SURGICAL INSTRUMENT$146
- DURYSTA$125
- VUITY$125
- EYLEA HD$125
- Oxervate$122
- Tecnis Simplicity$106
How this compares
$6,795 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 287 | $107,144 |
| RestasisCyclosporine | 129 | $106,751 |
| XiidraLifitegrast | 49 | $38,980 |
| CombiganBrimonidine Tartrate/Timolol | 149 | $37,709 |
| RocklatanNetarsudil Mesylat/Latanoprost | 77 | $29,537 |
| Alphagan PBrimonidine Tartrate | 107 | $28,062 |
| XdemvyLotilaner | 12 | $23,450 |
| VyzultaLatanoprostene Bunod | 40 | $14,769 |
| RhopressaNetarsudil Mesylate | 41 | $13,802 |
| MieboPerfluorohexyloctane/Pf | 17 | $13,108 |
| Cyclosporine | 31 | $10,753 |
| Brimonidine Tartrate | 124 | $6,738 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 55 | $3,813 |
| Travoprost | 29 | $3,378 |
| Latanoprost | 311 | $3,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $877 | $279,667672 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $667 | $66,857106 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $572 | $23,45012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in West Palm Beach
- Jodi LuchsWest Palm Beach$207K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.